Werewolf Therapeutics reports Q1 net loss of $16.2M; cash runway extended to Q1 2026

Werewolf Therapeutics, Inc.

2024-Q1 EPS reported -$0.39

Net loss $16.2M in Q1 2024, up from $12.0M loss in Q1 2023; R&D expenses rose to $12.9M.
Cash and equivalents $139.2M at March 31, 2024; new $60M loan from K2 HealthVentures ($30M drawn) extends runway through Q1 2026.
Collaboration revenue from Jazz Pharma fell to $0.7M from $4.5M YoY.
Planned ASCO 2024 presentation of WTX-124 combination dose-escalation data; Q2 interim data for WTX-330 monotherapy.
Preclinical advances: WTX-518 and WTX-712 show tumor regressions in mouse models; IL-10 for IBD presented at AAI.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Werewolf Therapeutics, Inc. reported first quarter ended March 31, 2024 results: revenue $0.7 million.

Period: first quarter ended March 31, 2024
Revenue: $0.7 million
Result: reported results

Exact text from the filing

be sufficient to fund operational expenses and capital expenditure requirements through at least the first quarter of 2026. • Collaboration revenue: Collaboration revenue was $0.7 million for the first quarter of 2024, compared to $4.5 million for the same period in 2023. Collaboration revenue consists of revenue recognized from the Company’s licensing agreement

View on SEC.gov

1362 earnings releases filed in the last 30 days. Browse all earnings releases →

Werewolf Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001785530-24-000018

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.